DuLac Farmaceutici, an Italian pharmaceutical company, is accelerating its expansion into the U.S. market with the launch of its products on OneLavi.com and its participation in the upcoming 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These strategic moves are part of DuLac's broader initiative to significantly grow its presence in the United States, following its initial success on Amazon U.S.
DuLac views the U.S. as a key long-term growth market and is pursuing a multi-channel approach to establish a strong foothold. By leveraging its existing Amazon demand, expanding e-commerce availability through OneLavi, and engaging directly with retailers through ECRM, the company aims to build a diversified national distribution network.
Gabriele Bollani, Founder and CEO of DuLac Farmaceutici, emphasized the importance of this phase: "ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market. Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."
The company's progress in the U.S. is evidenced by its performance on Amazon, where its Arnica Gel 98% has garnered over 13,000 customer reviews with an average rating of 4.5 stars, and its Dinaven line has received more than 4,000 reviews with a 4.6-star average. This consumer validation has paved the way for the addition of OneLavi, which now offers DuLac's Made in Italy products to a broader American audience.
Participation in the ECRM session adds a crucial business-to-business dimension to DuLac's U.S. strategy. During the event, DuLac will engage in scheduled meetings with buyers from major health, specialty, food, drug, and mass retail channels. These interactions provide an opportunity to showcase its Italian-developed product portfolio, pharmaceutical heritage, and advanced manufacturing capabilities to potential retail partners. The company will highlight its high-concentration Arnica Gel 98% range, as well as the Dinaven and Diosmin lines.
Beyond securing additional points of distribution, DuLac aims to establish lasting relationships that will support a larger and more diversified U.S. retail presence. The company brings over 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to this endeavor. Its product development and manufacturing capabilities include the proprietary Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, solvent-free Supercritical CO₂ Extraction, and adherence to internationally recognized GMP and ISO quality standards.
With Amazon as a foundation, OneLavi now live, and ECRM meetings on the horizon, DuLac is transitioning from initial market development to a broader national expansion strategy. The company's objective is to create a diversified U.S. presence across e-commerce, retail, wholesale, and other channels, while introducing more American consumers to its brand and Italian-developed products. This multi-pronged approach underscores DuLac's commitment to the U.S. market and its potential to become a significant player in the wellness and pharmaceutical sectors.
